GLP-1 agonists are regarded as the primary contenders for resmetirom
They also have excellent safety profile and lead to benefits independent of weight loss. For patients with diabetes, there have been studies showing that medical providers are less likely to prescribe certain medications to commercially insured patients who are Black, than they are to those who are white
And with J.P
Gouin T, Avalos J, Brunning I, Brzuska K, De Graaf J, Kaumanns J, et al
To support your weight loss journey, we customize a weight loss program using our GLP-1 medications like semaglutide and tirzepatide
Though adults aged 45 to 54 years make up for a sixth of the obesity population in the U.S., they account for nearly a quarter of those taking GLP-1 drugs